# A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions

> **NCT04363242** · PHASE1 · UNKNOWN · sponsor: **Synermore Biologics Co., Ltd.** · enrollment: 22 (actual)

## Conditions studied

- Epithelial Carcinoma
- Solid Tumor

## Interventions

- **BIOLOGICAL:** SYN125
- **BIOLOGICAL:** SYN004

## Key facts

- **NCT ID:** NCT04363242
- **Lead sponsor:** Synermore Biologics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-09
- **Primary completion:** 2023-07-31
- **Final completion:** 2023-09-30
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2023-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04363242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04363242, "A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04363242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*